The Efficacy of Rituximab in the Treatment of Membranous Nephropathy

  • Ruby Maharjan Department of Nephrology, Yan’an Hospital of Kunming Medical University
  • Jin Wen Wang Department of Nephrology, Yan’an Hospital of Kunming Medical University
  • Indra Kumar Shrestha Department of Anesthesiology, Second Affiliated Hospital of Kunming Medical University
DOI: https://doi.org/10.33314/jnhrc.v18i4.2481

Abstract

Rituximab is a chimeric monoclonal antibody directed against the CD20 expressed on B cells, originally used to treat lymphoma but is increasingly used for the treatment of autoimmune diseases. Membranous nephropathy is an autoimmune disease resulting from the deposition of IgG and complements components onto the subepithelial layer of the glomerular capillary wall and remains the leading cause of nephrotic syndrome in adults. Several prospective and retrospective studies showed rituximab induces remission and may decrease proteinuria in patients with membranous nephropathy. Considerable evidence supports the use of B-cell depletion as initial therapy in nephrotic patients with membranous nephropathy. This review focuses on the efficacy and safety of rituximab in the treatment of membranous nephropathy.
Keywords: Membranous nephropathy; rituximab; treatment

Published
2021-01-21
How to Cite
MaharjanR., WangJ. W., & ShresthaI. K. (2021). The Efficacy of Rituximab in the Treatment of Membranous Nephropathy . Journal of Nepal Health Research Council, 18(4), 580-587. https://doi.org/10.33314/jnhrc.v18i4.2481
Issue
Vol. 18 No. 4 (2020): Vol. 18 No. 4 Issue 49 Oct-Dec 2020
Section
Review Article

Copyright (c) 2021 Ruby Maharjan, Jin Wen Wang, Indra Kumar Shrestha

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Journal of Nepal Health Research Council JNHRC allows to read, download, copy, distribute, print, search, or link to the full texts of its articles and allow readers to use them for any other lawful purpose. Copyright is retained by author. The JNHRC work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0).